|Awarded On||November 02, 2011|
|Title||Biobetter Cancer Monoclonal Antibody Program|
|Program||Product Development Research|
|Award Mechanism||Company Commercialization|
|Principal Investigator/Program Director||Richard Holtz|
|Cancer Sites||Leukemia, Lymphoma|
This proposal will develop a “biobetter” Rituxan - a monoclonal antibody therapy that has dramatically changed the outlook for patients with Non-Hodgkin’s lymphoma and chronic lymphocytic leukemia. Our biobetter, produced in hydroponic plants, will have enhanced ability to kill cancer cells, but impose no additional risks or side effects to patients. Because of our unique plant-based biomanufacturing platform, the biobetter will be substantially less expensive, reducing costs by at least one third.
In the first two years of the project, we will develop the biobetter and perform all testing and preclinical evaluation required by the FDA. In the third year, we will perform the initial clinica...